» Articles » PMID: 39472701

High Protection and Transmission-blocking Immunity Elicited by Single-cycle SARS-CoV-2 Vaccine in Hamsters

Abstract

Vaccines have played a central role in combating the COVID-19 pandemic, but newly emerging SARS-CoV-2 variants are increasingly evading first-generation vaccine protection. To address this challenge, we designed "single-cycle infection SARS-CoV-2 viruses" (SCVs) that lack essential viral genes, possess distinctive immune-modulatory features, and exhibit an excellent safety profile in the Syrian hamster model. Animals intranasally vaccinated with an Envelope-gene-deleted vaccine candidate were fully protected against an autologous challenge with the SARS-CoV-2 virus through systemic and mucosal humoral immune responses. Additionally, the deletion of immune-downregulating viral genes in the vaccine construct prevented challenge virus transmission to contact animals. Moreover, vaccinated animals displayed neither tissue inflammation nor lung damage. Consequently, SCVs hold promising potential to induce potent protection against COVID-19, surpassing the immunity conferred by natural infection, as demonstrated in human immune cells.

References
1.
Tseng H, Ackerson B, Luo Y, Sy L, Talarico C, Tian Y . Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022; 28(5):1063-1071. PMC: 9117141. DOI: 10.1038/s41591-022-01753-y. View

2.
Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

3.
Singanayagam A, Hakki S, Dunning J, Madon K, Crone M, Koycheva A . Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2021; 22(2):183-195. PMC: 8554486. DOI: 10.1016/S1473-3099(21)00648-4. View

4.
Wang Y, Yang C, Song Y, Coleman J, Stawowczyk M, Tafrova J . Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc Natl Acad Sci U S A. 2021; 118(29). PMC: 8307828. DOI: 10.1073/pnas.2102775118. View

5.
Zhang Y, Chen Y, Li Y, Huang F, Luo B, Yuan Y . The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι. Proc Natl Acad Sci U S A. 2021; 118(23). PMC: 8201919. DOI: 10.1073/pnas.2024202118. View